Real-world comparison of cabazitaxel vs. 177-lutetium-PSMA radioligand therapy in metastatic castration resistant prostate cancer.

被引：0
|
作者：
Wenzel, Mike
Koll, Florestan
Hoeh, Benedikt
Humke, Clara
Siech, Carolin
Mader, Nicolai
Groener, Daniel
Steuber, Thomas
Graefen, Markus
Maurer, Tobias
Brandts, Christian H.
Banek, Severine
Chun, Felix
Mandel, Philipp
机构：
[1] Univ Hosp Frankfurt, Dept Urol, Frankfurt, Germany
[2] Goethe Univ Frankfurt, Univ Hosp Frankfurt, Dept Urol, Frankfurt, Germany
[3] Univ Hosp Frankfurt, Dept Nucl Med, Frankfurt, Germany
[4] Goethe Univ Frankfurt, Dept Nucl Med, Frankfurt, Germany
[5] Univ Hosp Hamburg Eppendorf, Martini Klin Prostate Canc Ctr, Hamburg, Germany
[6] Prostate Canc Ctr Hamburg, Martini Clin, Hamburg, Germany
[7] Goethe Univ Frankfurt, Frankfurt, Germany
[8] Goethe Univ Frankfurt, Dept Urol, Frankfurt, Germany
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2025年 / 43卷 / 5_SUPPL期
关键词：
D O I：
10.1200/JCO.2025.43.5_suppl.70
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Metastatic extent predicts survival as patients with metastatic castration-resistant prostate cancer are treated with 177Lu-PSMA radioligand therapy
    von Eyben, Finn Edler
    Kulkarni, Harshad R.
    Baum, Richard P.
    THERANOSTICS, 2020, 10 (11): : 4900 - 4902
  • [42] PSMA radioligand therapy rechallenging: expanding the therapeutic possibilities in metastatic castration resistant prostate cancer
    Volpe, Fabio
    Piscopo, Leandra
    Klain, Michele
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2024, 51 (13) : 4163 - 4164
  • [43] In-field progression following radiation therapy as a prognostic biomarker for lutetium-177-PSMA-617 response in metastatic castration-resistant prostate cancer.
    Howell, Jackson Neal
    Wilkes, Jacob
    Maughan, Nichole M.
    Morton, Kathryn
    Hu, Eric
    Gill, David Michael
    Samuelson, Scott James
    Boothe, Dustin
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (5_SUPPL)
  • [44] 177Lu -PSMA-I&T PSMA radioligand therapy in metastatic castration - resistant prostate cancer: First clinical trial in Asia
    Bu, Ting
    JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS, 2019, 62 : S527 - S528
  • [45] Systemic Therapy Update on 177Lutetium-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer: ASCO Rapid Recommendation
    Garje, Rohan
    Rumble, R. Bryan
    Parikh, Rahul A.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (31) : 3664 - +
  • [46] Lutetium-177 PSMA radioligand therapy for metastatic castration resistant prostate cancer in Germany: Population-based data with multicenter validation from 2016 to 2020.
    Flegar, Luka
    Thoduka, Smita George
    Librizzi, Damiano
    Luster, Markus
    Zacharis, Aristeidis
    Heers, Hendrik
    Eisenmenger, Nicole
    Ahmadzadehfar, Hojjat
    Eiber, Matthias
    Weber, Wolfgang A.
    Groeben, Christer
    Huber, Johannes
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [47] Olaparib vs Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer
    Wallis, Christopher J. D.
    Klaassen, Zachary
    Jackson, William C.
    Dess, Robert T.
    Reichert, Zachery R.
    Sun, Yilun
    Spratt, Daniel E.
    JAMA NETWORK OPEN, 2021, 4 (05) : E2110950
  • [48] 177Lu-PSMA-617 Radioligand Therapy in Metastatic Castration Resistant Prostate Cancer: Safety, Efficacy and Quality of Life Assessment
    Yadav, M. P.
    Bal, C.
    Ballal, S.
    Tripathi, M.
    Damle, N. A.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2019, 46 (SUPPL 1) : S646 - S646
  • [49] Therapeutic response and safety of radioligand therapy with 177Lu-PSMA-617 in metastatic castration-resistant prostate cancer patients
    Ashfaq, Wardah
    Rehman, Khurram
    Shahid, Abubaker
    Younis, Muhammad Numair
    MEDICAL ONCOLOGY, 2024, 41 (09)
  • [50] Radiobiological parameters for the assessment of 177Lu-PSMA-617 Radioligand Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer
    Hu, J.
    Xue, S.
    Mercolli, L.
    Sari, H.
    Rominger, A.
    Afshar-Oromieh, A.
    Shi, K.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2022, 49 (SUPPL 1) : S636 - S636
12345